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Abstract
Background: In the substantia nigra of Parkinson’s disease (PD) patients, increased lipid peroxidation, decreased
activities of the mitochondrial complex I of the respiratory chain, catalase and glutathione-peroxidase, and
decreased levels of reduced glutathione have been reported. These observations suggest that oxidative stress and
mitochondrial dysfunction play a role in the neurodegeneration in PD. We assessed enzymatic activities of
respiratory chain and other enzymes involved in oxidative processes in skin fibroblasts cultures of patients with PD.
Methods: We studied respiratory chain enzyme activities, activities of total, Cu/Zn- and Mn-superoxide-dismutase,
gluthatione-peroxidase and catalase, and coenzyme Q10 levels in skin fibroblasts cultures from 20 Parkinson’s
disease (PD) patients and 19 age- and sex- matched healthy controls.
Results: When compared with controls, PD patients showed significantly lower specific activities for complex V
(both corrected by citrate synthase activity and protein concentrations). Oxidized, reduced and total coenzyme Q10
levels (both corrected by citrate synthase and protein concentrations), and activities of total, Cu/Zn- and Mn-
superoxide-dismutase, gluthatione-peroxidase and catalase, did not differ significantly between PD-patients and
control groups. Values for enzyme activities in the PD group did not correlate with age at onset, duration, scores of
the Unified Parkinson’s Disease Rating scales and Hoehn-Yahr staging.
Conclusions: The main result of this study was the decreased activity of complex V in PD patients. This complex
synthesizes ATP from ADP using an electrochemical gradient generated by complexes I-IV. These results suggest
decreased energetic metabolism in fibroblasts of patients with PD.
Background
The pathogenesis of the neuronal degeneration of neu-
r o n si nt h ep a r sc o m p a c t ao ft h es u b s t a n t i an i g r ai n
patients with Parkinson’sd i s e a s e( P D )i su n k n o w n .T h e
discovery that the 1-methyl-4-phenyl-pyridinium ion
(MPP
+), the metabolite of the parkinsonism-inducing
neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) did inhibit complex I [1-3] led some investiga-
tors to examine the mitochondrial function in idiopathic
PD.
The mitochondrial respiratory chain consists of five
enzymatic complexes located within the inner mito-
chondrial membrane. Four enzymes (complexes I-IV)
transport electrons from NADH or succinate to oxygen,
and these complexes pump protons out of the mito-
chondria to form an electrochemical gradient. Complex
V (ATP synthase) uses that electrochemical gradient to
synthesize ATP from ADP.
Many studies have shown decreased complex I activity
in the substantia nigra of PD patients (reviewed in refer-
ence [4]). More recently, Parker et al. [5] found
decreased complex I activity in frontal cortex as well.
However, the results of studies measuring mitochondrial
complexes in peripheral tissues have been controversial
(reviewed in reference [4]). The activity of mitochondrial
complexes has been measured in the following tisues:
￿ Skeletal muscle (most studies performed with iso-
lated mitochondria). There have been reported nor-
mal activities of mitochondrial respiratory chain
complexes I-IV [6-10], or decreased activities of
complexes I [11-16], II [11-14] or IV [15-17].
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mitochondria). There have been reported normal
activities [6,18-20], or decreased activities of complex
I [21-26], complex II+III [25] or complex IV [24].
￿ Lymphocytes. Studies with homogenates showed
decreased activities of complex II [23] or complexes
I and IV [27], while studies with isolated mitochon-
dria showed normal activities [28], or decreased
activity of complexes I and I+III [29], and complex
IV [29].
￿ Leukocytes: Muftuoglu et al. [30] reported
decreased complexes I and IV activities in leukocytes
from patients with idiopathic PD, and decreased
complex I activity, with normality of complex IV, in
patients with parkin mutations.
￿ Spermatozoa. Our group showed similar mitochon-
drial respiratory chain enzymes activities corrected
by citrate synthase (CS), in the spermatozoa from
untreated PD patients [31].
A study on mitochondrial function of skin fibroblasts
from PD showed a deficiency in complexes I and IV
[32,33] that was partially restored with coenzyme Q10
treatment [33]. Piccoli et al. [34] examined mitochon-
drial respiratory function of a patient affected by early-
onset parkinsonism carrying the homozygous W437X
nonsense mutation in the PINK1 gene, and found
decreased complex IV activity and some depression of
the ATPase activity. In a recent study, Ferrer et al. [35]
have shown decreased levels of ATP synthase in the
substantia nigra and increased levels in the frontal cor-
tex of patients with PD.
The study of mitochondrial function in PD might be
important because, together with the classical descrip-
tion of oxidative stress and mitochondrial dysfunction in
the brains of patients with this disease, the identification
of specific gene mutations that cause PD has reinforced
their relevance. Proteins associated with familial PD,
such as PTEN-induced putative kinase 1 (PINK1), DJ-1,
alpha-synuclein, leucine-rich repeat kinase 2 (LRRK2)
and, possibly, parkin, are either mitochondrial proteins
or are associated with mitochondria, and have a role on
oxidative stress [36].
Some authors described decreased activities of the
antioxidant enzymes glutathione-peroxidase (GPx)
[37,38], total superoxide-dismutase (SOD) [39], Mn-
SOD [40], Cu,Zn-SOD [41], and catalase [37], in the
substantia nigra of PD patients; while Mn-SOD activity
in the cortex of PD patients has been found increased
[35,42]. GPx activity has been studied in serum or
plasma, erythrocytes, and neutrophils; total SOD, Cu,
Zn-SOD and/or Mn-SOD levels or activities in serum or
plasma, cerebrospinal fluid, erythrocytes, neutrophils,
platelets, and lymphocytes; and catalase activity in
erythrocytes from PD patients. The results of these stu-
dies (reviewed in reference [4]) are controversial. Piccoli
et al. [34], in their patient with the homozygous W437X
nonsense mutation in the PINK1 gene described normal
levels of total glutathione, reduced glutathione and glu-
tathione peroxidase activity, normal Cu/Zn-SOD activity
and a small decrease of the mitochondrial Mn-SOD in
fibroblasts. To our knowledge activity of catalase has
not been studied previously in fibroblasts.
Coenzyme Q10 (CoQ10) is the electron acceptor for
mitochondrial complexes I and II and a powerful anti-
oxidant [43]. Shults et al. [44] reported a correlation
between mitochondrial CoQ10 levels and activities of
complexes I and II/III. Gotz et al. [45] reported a
decreased [reduced CoQ10/oxidized CoQ10] ratio
(redox ratio) in untreated PD patients, that was further
decreased by levodopa treatment and partially restored
with selegiline. Serum or plasma CoQ10 levels have been
described decreased, normal or increased in some stu-
dies (reviewed in reference [4]). To our knowledge,
CoQ10 levels in fibroblasts of PD patients have not been
measured previosly.
The aim of this study was to assess the enzymatic
activities of respiratory chain enzymes and other
enzymes involved in oxidative processes, such as GPx,
SOD, catalase and coenzyme Q10 in skin fibroblast cul-
tures from patients with PD. The study was carried out
in skin fibroblasts because the specimens were easily
accessible and should be free of influence from medica-
tion, environmental hazards and other possible factors
contributing to oxidative stress.
Methods
Patients and controls
Twenty patients diagnosed with PD and 19 healthy age-
and sex-matched controls were enrolled in this study,
after informed consent. The study was approved by the
Ethics Committees of the University Hospitals “Doce de
Octubre” and “Príncipe de Asturias”, and was conducted
according to the declaration of Helsinki. Two patients
received no treatment, while the other 18 were treated
with antiparkinsonian drugs alone or in combination
including levodopa (16 cases), dopamine agonists (14
cases), selegiline or rasagiline (8 cases), anticholinergics
(3 cases), and amantadine (1 case).
The control group was composed by 19 patients
evaluated in the neurology departments of the same
hospitals because of tension type headache, dizziness,
dorsolumbar or cervical pain, etc. The clinical data of
PD patient and control groups are summarized in
table 1.
The following exclusion criteria were applied both to
patients and controls: A) Ethanol intake higher than 80
g/day in the last 6 months. B) Previous history of
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C) Previous history of severe systemic disease. D) Atypi-
cal dietary habits (diets constituted exclusively by one
type of foodstuff, such as vegetables, fruits, meat, or
others, special diets because of religious reasons, etc) F)
Intake of drugs which modify lipid absorption. G) Ther-
apy with vitamin supplements in the last 6 months.
Skin fibroblast cultures
Human skin fibroblasts were obtained from the dorsal
region of the upper arm of each PD patient or control.
Fibroblasts from the biopsy specimens were cultured in
Dulbecco’s modified Eagle’s medium containing penicillin
(100 UI/mL), streptomycin (100 mg/dl), L-glutamine (4
mM) and supplemented with heat-inactivated fetal calf
serum at 37°C in a humidified atmosphere of 95% air and
5% CO2.C e l l sw e r eg r o w nt oc o n f l u e n c e ,h a r v e s t e db y
trypsinization at 37°C, washed with culture medium and
resuspended with phosphate buffer 20 mM, and then soni-
cated to obtain the cell homogenate. Care was taken not to
use cultures with a passage number greater than 12.
Respiratory chain enzymes assay
Respiratory chain enzymes and citrate synthase activity
were measured in a DU-68 spectrophotometer (Beck-
man), applying 35-150 μg of total protein per 1 ml test
volume in every complex enzyme assay. Incubation tem-
peratures were 30°C for NADH coenzyme Q oxidore-
ductase (complex I), rotenone-sensitive NADH
cytochrome c reductase (complexes I and III), succinate
cytochrome c reductase (complexes II and III), succinate
dehydrogenase (complex II) and citrate synthase (CS),
and 38°C for cytochrome c oxidase (complex IV). The
activities of complexes II, I and III, II and III, IV, and
CS were determined as reported elsewhere [27]. Com-
plex I was measured by following the oxidation of
NADH at 340 nm in 100 mM Tris-HCl pH 7.4, 500
m Ms u c r o s e ,2m ME D T A ,5m MK C N ,1 0 0μM
NADH, and 50 μM DB (2,3-dimethyl-5-decyl-6-methyl-
benzoquinone) [46]. The reaction was inhibited by 90%
when 2 μM rotenone was present. Complex V was
determined by measuring 2.5 mM ATP extinction in a
mean with 50 mM Hepes-Mg buffer at pH 8.0, 0.2 mM
NADH, and phosphoenol-pyruvate 2.5 mM, and then
adding 5 μl of pyruvate-kinase (10 mg/ml) and 10 μLo f
lactate-dehydrogenase (5 mg/ml) in presence of 10 μlo f
antimycin A (0.2 mg/ml in 50% ethanol). The oligomy-
cin sensitive fraction was measured by adding 10 μlo f
oligomycin (0.2 mg/ml in 50% ethanol).To correct for
mitochondrial volume, all respiratory chain enzyme
activities were normalized to the activity of CS. Protein
were measured by the method of Lowry et al. [47]. Spe-
cific activities were expressed as nmol × min
-1 xmg pro-
tein
-1, and referred to the specific activities of CS to
correct for mitochondrial volume. All chemicals were
from Boehringer Mannheim (Boehringer Mannheim,
Germany) and Sigma Chemicals (St. Louis, MO). The
measures were performed three times for every sample
on three different passages (most of them between pas-
sage 5 and passage 10). The standard deviation of every
measure is specified in table 2. The range of linearity
was defined in all our determinations in a wide range of
Table 1 Clinical data of Parkinson’s disease (PD) and control patients groups
VARIABLE PARKINSON’S DISEASE (n = 20) CONTROLS (n = 19) p values
MEAN (SD) AGE (years) 59.2(15.6) 59.16 (10.7) n.s
SEX (F/M) 8/12 13/7
MEAN (SD) AGE AT ONSET OF PD (years) 51.1(10.2)
MEAN (SD) DURATION OF PD (years) 8.1(4.2)
Table 2 Mean (SD) respiratory chain enzymes activities
(expressed as nmol/min/mg protein) in skin fibroblast
cultures of patients with Parkinson’s disease (PD) and
controls (CS = citrate synthase)
VARIABLE PARKINSON’S DISEASE
(n = 20)
CONTROLS (n
= 19)
p
values
COMPLEX I/CS 34.56 (17.10) 26.13 (9.49) n.s.
COMPLEX II/CS 19.02 (3.22) 17.10 (2.77) n.s.
SDH/CS 14.45 (2.83) 12.71(3.35) n.s
COMPLEX III/CS 26.80 (7.97) 26.75 (5.86) n.s.
COMPLEX IV/CS 65.70 (10.83) 62.01 (9.61) n.s.
COMPLEX V/CS 41.57 (16.70) 52.52 (23.56) 0.021
COMPLEX I + III/CS 380.70 (88.90) 337.91 (58.85) n.s.
COMPLEX II + III/
CS
16.67 (5.03) 12.27 (3.33) n.s
CS/protein 77.39 (28.59) 74.27 (20.08) n.s
COMPLEX I/protein 26.70 (11.13) 22.48 (9.96) n.s.
COMPLEX II/
protein
13.73 (3.79) 13.22 (3.70) n.s.
SDH/protein 10.07 (2.85) 10.17 (3.70) n.s.
COMPLEX III/
protein
20.82 (9.20) 20.10 (7.51) n.s.
COMPLEX IV/
protein
44.49 (10.53) 44.49 (11.42) n.s.
COMPLEX V/
protein
29.95 (14.70) 42.21 (18.80) 0.017
COMPLEX I + III/
protein
253.76 (79.91) 247.25 (51.31) n.s.
COMPLEX II + III/
protein
9.89 (3.11) 9.48 (4.59) n.s.
del Hoyo et al. BMC Neurology 2010, 10:95
http://www.biomedcentral.com/1471-2377/10/95
Page 3 of 7protein concentration. So we decided to use the homo-
genates in order to have a total protein concentration of
35-150 micrograms per mililiter of final test volume.
This range was inside the linearity to all the activities of
the OXPHOS complexes.
Glutathione-peroxidase, catalase and superoxide-
dismutase isoenzymes determination
Glutathione peroxidase specific activity was determined
according to the method described by Flohé and Gün-
zler [48] based on NADPH oxidation followed at 340
nm at 37°C.
Catalase activity was determined according to the
method described by Aeby [49] based on H2O2 decom-
position followed at 240 nm at room temperature. Cata-
lase specific activity was determined by calculating the
rate constant of a first order reaction.
Total and Mn-SOD activities were determined accord-
ing to the method described by Spitz and Oberley [50]
based on nitroblue tetrazolium reduction by superoxide
radicals followed at 560 nm at room temperature. The
Mn-SOD was distinguished from cyanide-sensitive Cu/
Zn-SOD by the addition of 5 mM NaCN. Cu/Zn-SOD
activity was calculated by substracting the cyanide-resis-
tant SOD activity form the total SOD activity. One unit
of SOD activity is defined as the amount of enzyme that
inhibits the reaction rate by 50%.
All enzymatic activities were expressed as values nor-
malized to total cellular protein. The measurements
were performed three times for every sample.
Coenzyme Q10 determinations
Oxidized, reduced and total coenzyme Q10 levels were
determined by high performance liquid chromatography
with electrochemical detection. The method used was
that of Langedijk et al. [51] with some modifications. The
stationary phase was a reverse phase column (HR-80 RP-
C18, 80 × 4,6 mm. ESA Inc). The mobile phase was pre-
pared by dissolving 7 g of NaClO4.H2O in 1000 ml of
methanol/propanol/HClO4 70%, 700.8:200:0.2 (vol/vol),
and the flow rate was set at 0.8 ml/min. The programmed
conditions for the electrochemical detector and the post-
column valve were the same. The system was entirely
controlled by a computer (Kromasystem 2000, Kontron
Instruments). Injections were made in a 50 μl injection
valve (Model 7161, Rheodyne, Cotaty, USA) with a 100 μl
syringe from Hamilton (Bonaduz, Switzerland). The cali-
bration method used ubiquinone as external standard.
The within-run coefficients of variation for CoQ10 and
CoQH2 were, respectively, 5 and 3.2%, and the day to day
precisions were 9.2 and 6.3%. CoQ10 recovery ranged
between 88 and 93%. The measurements of CoQ10 were
expressed in nmol/g of protein. The measures were per-
formed three times for every sample.
Statistical analysis
Results were expressed as mean ± SD. Statistical analysis
was done by the SPSS statistical package (15.0 version).
For continuous variables the Kolmogorov-Smirnoff test
was used to analyze normality in the distribution. Then,
the Students’s two-sample t-test was used for variables
that followed a normal distribution and the Mann-Whit-
ney test was used for the rest of variables. The results of
each table were corrected for multiple comparisons by
the use of Bonferroni’s correction. Correlation analyses
were performed by using Pearson’sc o r r e l a t i o n
coefficient.
Results
The results are summarized in tables 2 and 3. When
compared with controls, PD patients showed signifi-
cantly lower specific activities for complex V (both cor-
rected by citrate synthase activity and protein
concentrations, table 2, figure 1). Oxidized, reduced and
total coenzyme Q10 levels (both corrected by citrate
synthase and protein concentrations), and activities of
total, Cu/Zn- and Mn-superoxide-dismutase, glutha-
tione-peroxidase and catalase, did not differ significantly
between PD-patients and control groups (table 3).
Values for enzyme activities in the PD group did not
correlate with age at onset, duration, scores of the Uni-
fied Parkinson’s Disease Rating scales and Hoehn-Yahr
staging.
Table 3 Mean (SD) superoxide-dismutase (SOD),
glutathione-peroxidase (GPx), and catalase activities
(expressed as units/mg protein); and concentrations of
coenzyme Q10 (expressed in nmol/g protein) in skin
fibroblast cultures of patients with Parkinson’s disease
(PD) and controls (CS = citrate synthase).
VARIABLE PARKINSON’S DISEASE
(n = 20)
CONTROLS (n
= 19)
p
values
REDUCED CoQ10/CS 0.41 (0.16) 0.34 (0.11) n.s.
OXIDIZED CoQ10/CS 0.75 (0.26) 0.63 (0.23) n.s.
TOTAL CoQ10/CS 1.16 (0.33) 0.97 (0.25) n.s.
REDUCED CoQ10/
protein
24.50 (7.38) 24.50 (7.38) n.s.
OXIDIZED CoQ10/
protein
56.49 (25.20) 47.31 (23.50) n.s.
TOTAL CoQ10/
protein
86.27 (29.07) 71.86 (26.38) n.s.
OXIDIZED Q10/
Reduced Q10
0.60 (0.27) 0.62 (0.27) n.s.
MnSOD/protein 14.20 (8.84) 11.76 (7.88) n.s.
CuZnSOD/protein 8.80 (7.08) 8.90 (6.87) n.s.
TOTAL SOD/protein 26.00 (8.58) 20.72 (11.52) n.s.
GPx/protein 13.03 (4.96) 14.45 (6.47) n.s.
CATALASE/protein 9.71 (5.20) 7.26 (2.05) n.s.
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The results of the present study showed that in PD
patients there was a decreased activity of mitochondrial
respiratory chain complex V, corrected by CS activity, in
skin fibroblast cultures. The results on complexes I and
IV in this study did not differ significantly between PD
patients and control groups, and none of our patients
showed decreased activities of these complexes. These
results contrast with those reported by other group
[32,33], who found a deficiency in complexes I and IV
activities, specially in a subgroup of PD patients com-
pared with controls, using skin fibroblast cultures as
well. This deficiency was partially restored with coen-
zyme Q10 treatment [33].
The discrepancies between the results on complex I
and IV of the present study and those of Winkler-Stuck
et al. [32,33] could be related with several methodologi-
cal reasons. These authors found enhanced flux control
coefficient of complex I and IV. This kind of variation
was measured using inhibitor titrations and calculating
the flux control coefficients from titration curves. The
method used by Winkler-Stuck et al. [32,33] is different
from that used in our study, because we only have mea-
sured, in the case of mitochondrial respiratory chain
complex activities, the activity of every complex, and
not the flux control coefficient. In addition, the control
groups were different, because while Winkler-Stuck et
al. [32,33] included patients who performed muscle
biopsy because they had discrete myopathic EMG
abnormalities but withoutt biopsy evidence of myopathy,
while our control patients had no clinical symptoms or
signs suggesting myopathy. Winkler-Stuck et al. [32,33]
did not measure complex V activity.
Our results suggest that decreased complex I activity
seen in the substantia nigra of PD patients is not a
generalised phenomenon. It is of note that complex V
has not been usually studied neither in brain nor in per-
ipheral tissues from PD patients. Indeed, complex V was
not measured in previous studies by our group using
isolated mitochondria from lymphocytes [27] or sperma-
tozoa [31] or in other report using skin fibroblasts
[32,33]. Cardellach et al. [15] found decreased complex
V activity in muscle of 2 out of their 8 parkinsonian
patients and, more recently, Ferrer et al. [35] found
decreased levels of ATP-synthase (complex V) in the
substantia nigra and increased levels of this enzymatic
complex in the frontal cortex of patients with PD.
The activities of Cu/Zn- and Mn-SOD, GPx, and cata-
lase, and the oxidized, reduced, and total CoQ10 levels
in skin fibroblasts of PD patients were similar to those
of controls. To our knowledge, these values have not
been previously measured in this tissue form, with the
exception of the single patient with a mutation in the
PINK1 gene reported by Piccoli et al. [34]. These results
do not rule out the possibility that there may be regio-
nal deficiencies of the activities of these enzymes and of
CoQ10 concentrations in some areas of the brain. More-
over, none of the enzymatic activities measured was cor-
related with the analyzed clinical features of PD.
Conclusions
The main result of the present study in skin fibroblasts
cultures suggests a possible contribution of the deficiency
of complex V activity, but not of other enzymes related
with oxidative stress, to the pathogenesis of PD. This
result is in agreement with that reported by Ferrer et al
[35] in the PD substantia nigra, which was interpreted by
the authors as related with neuronal loss. Complex V is
involved in the synthesis of ATP from ADP, and is very
important in the energetic metabolism of the cells. The
result of the present study suggests decreased energetic
metabolism in fibroblasts of patients with PD.
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